Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
92.06 CHF | +0.91% | +0.34% | +8.46% |
10:34am | Novartis: efficacy of remibrutinib in urticaria -USC | CF |
05:41am | Novartis' Chronic Spontaneous Urticaria Treatment Shows Long-term Efficacy in Late-stage Trial Data | MT |
Official Publications
- Stock Market
- Equities
- NOVN Stock
- News Novartis AG
- Official Publications